Categories
Latest Industry Intelligence
The latest eBook by DDW is out now. This 28-page eBook, sponsored by Benchling, examines [...]
Discover the groundbreaking findings from a study on bispecific T cell engagers conducted by The [...]
…in the UK. The Covid-19 pandemic may now be declared officially over, but the boost in trust that the sector enjoyed as a result of its role in combating it…
…2022 of DDW. They are called “Talking Tech” and “Rejuvenation biotech: Can this company make age a thing of the past?” With Covid-19 taking so much of the drug discovery…
…emergence of the novel coronavirus and the crisis it caused. In this episode, Kelland shares what she means by the ‘next pandemic’, the lessons learnt from the Covid-19 pandemic, and…
The term ‘PCR’ has been on everybody’s lips since the outbreak of the Covid-19 pandemic, but only laboratory professionals know how difficult it can be to achieve success with this…
…will begin soon.” Additional limitations include relatively short follow-up time and some setbacks, including cancer vaccine shortage, during the Covid-19 pandemic. According to Sullivan, a technical limitation of the neoantigen…
…be ready by 2030, and a new treatment for long Covid fatigue could be available soon. There is also new hope for sepsis treatment and for preventing cardiovascular disease in…
…from long Covid fatigue may be in sight. Our approach allows us to target several pathways that are disrupted in long Covid, and our previous experience with AXA1125 suggests that…
…12 to 18 months owing to the success of the Covid-19 mRNA jab1. Dr Paul Burton, the Chief Medical Officer of Moderna, told the Guardian: “We will have that vaccine…